A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
Montefiore Medical Center
Memorial Sloan Kettering Cancer Center
Avera McKennan Hospital & University Health Center
City of Hope Medical Center
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
Wake Forest University Health Sciences
Mayo Clinic
University of California, Irvine
Sichuan Enray Pharmaceutical Sciences Company
Essen Biotech
University of Colorado, Denver
Institut Bergonié
Royal Marsden NHS Foundation Trust
Grey Wolf Therapeutics
University of Nebraska
Medical College of Wisconsin
Mayo Clinic
RenJi Hospital
University Health Network, Toronto
Cancer Research UK
University Health Network, Toronto
Hospices Civils de Lyon
Hadassah Medical Organization
Washington University School of Medicine
Washington University School of Medicine
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Dana-Farber Cancer Institute
Sichuan Enray Pharmaceutical Sciences Company
The Netherlands Cancer Institute
Institut Bergonié
University of California, Irvine
Yonsei University
Cancer Research UK
Centre Georges Francois Leclerc
M.D. Anderson Cancer Center
N.N. Petrov National Medical Research Center of Oncology
University of Alberta
Arbeitsgemeinschaft medikamentoese Tumortherapie
Tomsk National Research Medical Center of the Russian Academy of Sciences
Rutgers, The State University of New Jersey
Stanford University
University Health Network, Toronto
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Second Affiliated Hospital of Guangzhou Medical University
Second Affiliated Hospital of Guangzhou Medical University